Chemical and advanced materials maker, Celanese Corporation CE declared that it is showcasing high quality, medical grade engineered polymers at the Drug Delivery to the Lungs Forum (DDL 26) at the Edinburgh International Conference Center, Scotland, UK from Dec 9-11, 2015.
Celanese will showcase its Hostaform MT SlideX POM product, a thermoplastic polymer that is an excellent low-friction solution for pressurized Metered Dose Inhalers (pMDIs), dry powder inhalers and spray pumps.
Celanese continues to expand its engineered polymers portfolio to deliver innovative material solutions that will meet the growing demands of medical suppliers worldwide and also provide innovative material solutions to the end users.
Celanese’s third-quarter 2015 adjusted earnings (excluding one-time items) of $1.50 per share fell 6.8% from $1.61 per share reported in the year-ago quarter. Earnings, however, topped the Zacks Consensus Estimate of $1.38. The results were aided by the company’s continued focus on opportunities to serve key markets and productivity initiatives.
Sales in the reported quarter were $1,413 million, down roughly 20.1% year over year. It also missed the Zacks Consensus Estimate of $1,548 million.
Per management, Celanese is confident that it can drive performance through the rest of 2015 despite currency headwinds and a challenging macro environment, especially the recent volatility in China. Celanese expects to offset these headwinds with its focus to create customer value to match market needs on moderate macroeconomic trends. This led the company to raise its adjusted earnings outlook to a range of $5.90–$6.10 per share (from $5.70-$6.00 per share) for 2015.
Celanese currently sports a Zacks Rank #1 (Strong Buy).
Other companies in the diversified chemical space worth considering include Innospec Inc. IOSP, Akzo Nobel N.V. AKZOY and The Dow Chemical Company DOW. While Innospec sports a Zacks Rank #1, both Akzo Nobel and Dow carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment